Skip to content
Search

Latest Stories

Ruling overturned in pharmaceutical case against Lexon UK, Medreich

The CMA spent millions of pounds in legal fees, taxpayers' money in order to pursue a claim that wasn't appropriate.

Ruling overturned in pharmaceutical case against Lexon UK, Medreich

AN INDEPENDENT tribunal has quashed a ruling made against directors at four pharmaceutical companies over allegations of entering into a non-competitive agreement over anti-nausea drug, with investigators stating there were “material errors” made in the case.

Two British Asian-owned companies, Lexon UK and Medreich, as well Alliance Pharma and Focus Pharmaceuticals were wrongfully accused in a case that caused financial and reputational damage to those involved.


When the allegation was initially raised in 2019, Lexon UK founder Nitin Sodha was chairman of the National Pharmacy Association (NPA) but stepped aside from his role as he was also the director and shareholder of Lexon UK.

A family source told Eastern Eye that Sodha wanted the NPA to continue its focus on supporting its members and securing a sustainable future for independent pharmacies and not be distracted by CMA allegations.

The CMA spent millions of pounds in legal fees, taxpayers’ money in order to pursue a claim that wasn’t appropriate. The parties subject to these allegations may be eligible to pursue a cost claim from the CMA, the source added.

The CMA claimed that from 2013 to 2018, manufacturers Alliance Pharma came to an agreement with Focus Pharmaceuticals, Medreich and Lexon UK that the trio would not get a licence to sell the same product in exchange for a profit share. As a result, the price of the drug prochlorperazine, an antinausea medicine often taken by chemotherapy patients, rose by 700 per cent – costing the NHS millions.

However, on Friday (25), the CMA quashed the £30 million fine against the four organisations and withdrew the disqualification orders against the directors who are no longer implicated in any wrongdoing.

“Having considered all the evidence and all of the submissions made by the parties, we find that Alliance and Lexon did not enter into the MEA. There was no such agreement,” said the Competition Appeal Tribunal (CAT).

“As we have found that there is no MEA and accordingly there was no breach of competition law, the issue of penalty does not arise.”

The affected directors include Pritesh Sonpal (Lexon UK), Peter Butterfield and John Dawson (Alliance Pharmaceuticals), Mark Cresswell, Roland Brown and Graeme Duncan (Focus Pharmaceuticals) and Debangshu Dey (Medreich).

Sonpal is part of a family business that had its beginning in the pharmacy sector when his uncle Nitin Sodha, who came to the UK from Kenya as a teenager, set up Knights Pharmacy from a porta-cabin in Redditch in 1984.

Sodha, along with his brothers Pankaj and Anup and nephew (Sonpal), set up Lexon UK in 1995 and grew it into one the country’s largest shortline wholesalers based in the Midlands.

He left the company in April last year after it was sold to the Bestway Group, which also runs Well Pharmacy.

Lexon serves 3,000 retail pharmacy customers as well as community pharmacies across the Midlands, northwest and the northeast of England.

It sold 42 community pharmacies (currently trading as Knights Pharmacy) to Well Pharmacy, but retains 50 branches.

More For You

Prudential to list Indian asset management venture

Prudential chief executive Anil Wadhwani

Prudential to list Indian asset management venture

INSURER Prudential plc announced that it is considering a partial listing of its stake in ICICI Prudential Asset Management, one of India's leading investment firms. The news sent Prudential's shares soaring by 5.8 per cent to close at 722p on the London Stock Exchange.

The FTSE 100 company currently holds a 49 per cent stake in the Indian joint venture, which market analysts estimate to be worth around £4 billion. ICICI Bank, which owns the remaining 51 per cent, has confirmed its intention to maintain its majority shareholding, emphasising its "long-term commitment" to the partnership that began in 1998, reported the Times.

Keep ReadingShow less
NatWest-Reuters

The bank has set a new performance target, aiming for a return on tangible equity of 15-16 per cent in 2025 and above 15 per cent by 2027. (Photo: Reuters)

What’s driving NatWest’s better-than-expected profit growth?

NATWEST reported higher-than-expected annual profit on Friday, supported by its growth strategy, improved productivity, and capital management efforts.

The bank, which once had assets worth 2.2 trillion pounds—more than twice the size of the British economy—has undergone years of restructuring to focus mainly on domestic consumer and mortgage lending.

Keep ReadingShow less
London business district
A general view shows the London's financial district from an office window in Canary Wharf. (Photo: Getty Images)

Economy grows 0.1 per cent in fourth quarter, defying expectations

THE UK economy expanded by 0.1 per cent in the final quarter of 2024, contrary to forecasts of a contraction, according to official data released on Thursday.

The growth, supported by a stronger-than-expected 0.4 per cent rise in December, offers some relief to chancellor Rachel Reeves as she navigates broader economic challenges.

Keep ReadingShow less
BP-Reuters

Fourth-quarter profit dropped 61 per cent compared to the previous year, marking BP’s weakest results since Q4 2020, when the pandemic reduced global oil demand. (Photo: Reuters)

BP reports lowest quarterly profit in four years, plans strategy reset

BP reported a quarterly profit of £943 million on Tuesday, falling short of expectations and marking its lowest in four years.

The company said it plans a "fundamental reset" of its strategy, days after reports that Elliott Management had taken a stake in the oil major.

Keep ReadingShow less
Shein-Reuters

Shein had aimed to go public in London in the first half of this year, subject to regulatory approvals in the UK and China. (Photo: Reuters)

Shein cuts valuation to £40 billion for London listing

SHEIN is preparing to lower its valuation to around £40 billion for a potential initial public offering (IPO) in London, according to three Reuters sources familiar with the matter.

This is nearly 25 per cent lower than the company's 2023 fundraising valuation as it faces increasing challenges.

Keep ReadingShow less